SPONSOR
Boryung Pharmaceutical Co., Ltd
Total Trials
2
Recruiting
2
Phases
Phase 1
NCT06126016
Recruiting
A Observational Study to Evaluate the Efficacy and Safety of Pacitol Inj.
Chronic Kidney Disease 5D
NCT07069335 Phase 1
Recruiting
A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer
Ovarian Cancer